The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening

Abstract Objective To determine whether serum fructosamine correlates with glycemic control and clinical outcomes in patients being screened for cystic fibrosis-related diabetes (CFRD). Methods Fructosamine and percent predicted forced expiratory volume in 1s (FEV 1 ) were measured in patients undergoing a 2h oral glucose tolerance test (OGTT) for CFRD screening. Fractional serum fructosamine (FSF) was calculated as fructosamine/total protein. Results FSF exhibited a positive correlation with 2h OGTT results (r 2 =0.3201, p =0.009), and ROC curve analysis suggested that FSF can identify patients with an abnormal OGTT (AUC=0.840, p =0.0002). FSF also exhibited a negative correlation with FEV 1 (r 2 =0.3732, p =0.035). Patients with FSF≥3.70μmol/g had significantly lower FEV 1 (median 47%) compared to those with FSF p =0.015). Conclusions FSF correlated with both OGTT results and FEV 1 , and reliably identified patients with abnormal OGTT results. This simple blood test shows potential as an effective tool in CFRD screening.